Drug Trial Radar · NCT06345794
A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Apr 3, 2024
Primary completion
Jun 18, 2024
Study completion Jun 18, 2024
Sponsor
- Lead sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853) in healthy participants. The study will also evaluate the safety and tolerability of LY4100511 (DICE-853) with itraconazole, fluconazole, and carbamazepine.
Conditions
- Healthy
Interventions
LY4100511 (DC-853)Drug
Administered orally.
ItraconazoleDrug
Administered orally.
FluconazoleDrug
Administered orally.
CarbamazepineDrug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4100511 (DC-853)Time frame: Predose up to 26 Days
- PK: PK: Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration (AUC[0-t]) of LY4100511 (DC-853)Time frame: Predose up to 26 Days
- PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY4100511 (DC-853)Time frame: Predose up to 26 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON San Antonio Clinical Research Unit
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.